“BPH is currently consider a common- progressive enlargement of the prostate gal caused by benign overgrowth of chiefly glandular tissue that occurs especially in some men > 50 years old and that tends to obstruct urination by constricting the urethra with heavy symptomatology and related consequences in quality of life. The current pharmacological therapy (based on 5-ARI, alfa blockers, antimicrobials, phototherapies, anti-Floosy Anti-edemogen and other) can and must be improved to delay or avoid surgery. To introduce new- pharmacological strategy is crucial to observe the immune implications in BPH. Reports in the biomedical literature database indicate that in BPH progression some of the following factors are heavily involved: Bacterial/ viral prostate infections, chronic chlorosis, hormonal factors. Autoimmune reactions, Urinary relux, Diet, Seating bathroom habits/behavior, sedentary, Pelvic congestion, Proctities, Prostate ducts obstructions, microcalcifications. All this fact contributes to an increased production of prognosis mediator’s growth factors (stromal and epithelial) in a vicious cycle and as a result, increase glands and complication of the pathogenic- conditions. The presence of immune- system in prostate prostate tissue is very well alive and manifest itself in different forms, from an infiltration of lymphocytes T and macrophages caused by chlorosis to cytokines that cause hypertrophy. These reactions along with the cellular damage produce ROS reactive oxygen species, increase in production of growth factors (like VGEF, IL 8 FGF 7, TGFB, FGF 2 and others), inhibition of apoptosis and tissue remodeling with hyperproduction of extracellular matrix and stromal parts. Other factor that can be responsible in the relapse in chronic prostatitis in BPH are micro-calcifications, obstruction of the ducts. But there are still other conditions that can be involved, such as metabolic syndrome, diabetes and the related biochemical and hormonal factors that can modify the metabolisms that can worsen the pathogenesis. other factors still play in. Ex. the command-/-control of the nervous systems over the bladder, ureteral restrictions and other Urological disease can cause important complications. The creation of a biofilm over the prostate capsule gland makes the penetration of several antimicrobial agents look like resistant which reduces their prostatic influx. Be patient it’s not over yet, we can still mention the complications caused by such as IPB, urinary reflux (chemical cystitis and prostatitis), prostate cancer and other factors.

Often Intestinal functional abnormalities and pathologies, anorectal, sexually- transmitted infectious as complication due to bacterial sanctuaries and intraprostatic calcifications. A bacterial infection can be primary or secondary (bacteria that causes infections or super-infectious in a tissue affected by chlorosis or to other conditions), for example in hypertonic pelvic sphinctermuscle. (Bacteria can come across also the lymphatic way (from rectum), by emetic way, rising ureteral infectious). Adrenergic- Petronus of prostate capsule contribute to BPH physio-pathology. Involved often Intestinal functional abnormalities and pathology “[15].

“It is known that the prostate is frequently involved in various pathologies in adults and elderly patients. Benignant o/malignant: anatomic of functionally disease. Frequently other condition like bladder dysfunctions can be associated or added to this pathology or caudated by it. Some of these pathologic conditions give lowlevel in-patient quality of life and reducing in life expectance (malignant). Malignant pathologies even start as local disease but can diffused as metastatic interesting other apparatus of the patient (patient frequently show resistance to first line therapy in example hormonal blocks, or different chemotherapy). But in this pathology, we can see a not complete resolution with current medical therapy in all patients and this can be related with the difficulties of some drugs molecules to penetrate adequately in the tissue. In ex. I many benignant cases as IPER-TROPHIA also phototherapy produces, or dietetic integrator are frequently added by the urologist to the classic drugs polytherapy. This fact shows that the classic drug therapy can be improved. In Relapses in bacterial chronic prostatitis are commonly in great number of patients, even under the best pharmacological therapies available today. It means that something goes wrong in this pharmacological therapy.

About bacterial chronic prostatitis we can see that some antimicrobials are used for long time cycle in order to have efficiently concentration of the drugs in a sanctuaries tissue as prostatic, but this not gives a healing to the entire patient treated and we can have toxicity not irrelevant. We can have different problems: Antimicrobial activity to cover the bacteria spectrum and the concentration active in the tissue for the right time necessary (Dynamic and kinetics). So, the answer today is: Have the right drugs today, need we knew delivery system to produce rely ERLICH MUGIC BULLET especially for prostatic tissue? We think that this clinical and therapeutic need in underestimate by pharmaceutical industries (our opinion). Why is today accepted to give great amount of antimicrobial to cure this kind of disease with high number of relapses (augmented toxicity for the patient and diffusion of resistances). Analyzing the literature, we can see that adding the clinical pharmacist competence in many medical teams we can have global increase in clinical outcomes.

We can think that the same we can have in some pathology with high relapses as chronic prostatitis but also in malignant cases (chemotherapy and other class of molecule available today) we can see that different chemotherapy drugs are used but patien with resistance can die by metastatic disease (Different drugs, with different way of action). If we know that there is a problem of ph. Kinetics and dynamics of drugs, we must clearly say that we need a really new approach to make possible the drug’s efficacy act in site of actions as request for an efficiently therapy. It is clear that the drugs vehicle is important as the same drugs and that modifying the molecule, we can improve the activity in relevant way also due in example a different tissue diffusion (In example in first chinooks vs fluoroquinolones).

Lipophilic- hydrophilic balances great influence the pk. Kinetics, VD or T1/2 but also the profile of linked chemical groups can give new delivery of classic drugs (Other can be acid or basic molecular properties or velocity in metabolism). In ex. see the activity of some MABS linked with radio isotopes in order to send the radioactivity in specific target reducing the complex toxicity. The specific Expertise of clinical pharmacy added to the medical team and to the pharmaceutical industries can help in finding new efficacy solution in drug delivery. Medicinal- chemistry knowledge added to advanced pharmacokinetics and dynamics, metabolism and Toxicology of clinical pharmacist can drive the pharmaceutical industries in the right direction.

The same a deep knowledge in resistance mechanism (drugs extrusion from intracellular and other) can be a great instrument in drugs design. In ex. it is showed that some intracellular chemotherapy is extruded by the cell like a normal poison. The same genomic mechanism of resistances and modified enzymatic level, target modify, can make the difference in clinical outcomes. Observing some relevant biomedical literature, we can see that if in acute situation we have seen a positive impact in improving clinical outcomes as in ICT medical team due by active participation of the clinical pharmacist we can have same improvement also in chronic condition [16]. “According Biomedical Literature published responsible of relapses of chronic prostatitis and relapses can be: biofilm, reduced urinary prostatic fluss in example: by IPB, urinary reflux (chemical cystitis and prostatitis), prostatic cancer et other factors” [17].

Xu Z et al. [18]: “Evidence confirmed that BPH/LUTS is strictly related to erectile dysfunction (ED) and significantly affects the quality of life of elderly males. Phosphodiesterase 5 inhibitors (PDE5i) can improve both ED and BPH/LUTS of the patients and PDE5 is expected to be a new therapeutic target for BPH/LUTS with ED” [18].

Magri V et al. [19]: “The complex network of etiological factors, signals and tissue responses involved in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) cannot be successfully targeted by a single therapeutic agent. Multimodalapproaches to the therapy of CP/CPPS have been and are currently being tested, as in the frame of complex diagnostic-therapeutic phenotypic approaches such as the urinary, psychosocial, organspecific, infection, neurological and muscle tenderness (UPOINTS) system. Patients received α-blockers, Serena ripens extracts combined or not with supplements (lycopene and selenium) and in the presence of documented or highly suspected infection, antibacterial agents. Combination treatment induced marked and significant improvements of National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) prostatitis symptom scores, International Index of Erectile Function (IIEF) sexual dysfunction scores, urinary peak flow rates and bladder voiding efficiency. A clinically appreciable reduction of ≥6 points of the total NIH-CPSI score was achieved in 77.5% of patients subjected to combination therapy for a period of 6 months. When the patients were divided in 3 cohorts, depending on the diagnosis of CP/CPPS [inflammatory (IIIa) vs. non-inflammatory (IIIc) subtypes, significant improvements of all signs and symptoms of the syndrome were observed in both cohorts at the end of therapy. A simple protocol based on α-blockers, S. ripens extracts and supplements and antibacterial agents, targeting the urinary, organ specific and infection domains of UPOINTS, may induce a clinically appreciable improvement of the signs and symptoms of CP/CPPS in a considerable percentage of patients. In patients not- responding sufficiently to such therapy,2-line agents (antidepressants, anxiolytics, muscle relaxants, 5-phosphodiesterase inhibitors and others) may be administered in order to achieve a satisfactory therapeutic response” [19].

Ozaki T et al. [20]: “Cav3.2 T-type Ca2+ channel activity is suppressed by zinc that binds to the extra-cellular histidine-191 of Cav3.2 and enhanced by H2S that interacts with zinc. Cav3.2 in nociceptors is upregulated in an activity-dependent manner. The enhanced Cav3.2 activity by H2S formed by the upregulated cystathionine-γ-lyase (CSE) is involved in the cyclophosphamide -induced cystitis-related bladder pain in the mice. We thus asked if the zinc deficiency affects the cystitis-related bladder pain in mice by altering Cav3.2 function and/or expression. Dietary zinc deficiency for 2 weeks greatly decreased zinc concentrations in the plasma but not bladder tissue and enhanced the bladder pain/referred hyperalgesia (BP/RH) following CPA at 200mg/ kg, a subeffective dose, but not 400mg/kg, a maximal dose, an effect abolished by pharmacological- blockade or gene silencing of Cav3.2. Together, zinc deficiency promotes bladder pain accompanying CPA-induced cystitis by enhancing function and expression of Cav3.2 in nociceptors, suggesting a novel therapeutic avenue for treatment of bladder pain, such as zinc supplementation” [20].

Lovick TA [21]: “Afferent input from Aδ and C-fibres innervating the urinary bladder are processed differently by the brain and have different roles in signaling bladder sensation. Aδ fibres that signal bladder filling activate a spin-bulb-spinal loop, which relays in the midbrain periaqueductal grey (PAG) and pontine micturition center (PMC). The excitability of this circuitry is regulated by tonic GABAergic inhibitory processes. In humans and socialized animals’ micturition is normally under volitional control and influenced by a host of psychosocial factors. Higher nervous decision-making in a social context to ‘go now’ or ‘do not go’ probably resides in frontal cortical- areas, which act as a central control switch for micturition. Exposure to psychosocial stress can have profoundly disruptive influence on the process and lead to maladaptive changes in the bladder. During sleeping the voiding reflex threshold appears to be reset to a higher level to promote urinary continence. Under physiological conditions C-fibre bladder afferents are normally silent but are activated in inflammatory bladder states and by intense distending pressure. Following prolonged stimulation visceral nociceptors sensitise, leading to a lowered threshold and heightened sensitivity. Sensitization may occur within the central- pain processing circuitry, which outlasts the original nociceptive insult. Visceral nociception may also be influenced by genetic and environmental influences. A period of chronic stress can produce increased sensitivity to visceral pain that lasts for months. Adverse early life events can produce even longer lasting epigenetic changes, which increase the individual’s susceptibility to developing visceral pain states in adulthood” [21].

Tonon L et al. [22]: “Causes of high mortality of prostate cancer in men of African ancestry living in the French- West Indies are still debated, (suspicions of environmental factors and the genetic susceptibility). The results show that African- Caribbean tumours are characterized by a more frequent deletion at 1q41- 43 encompassing the DNA repair gene PARP1, and a higher proportion of intrachromosomal rearrangements including duplications associated with CDK12 truncating- mutations. Transcriptome- analyses show an overexpression of genes related to androgen receptor- activity in African Caribbean tumours, and of PVT1, a long non-coding RNA located at 8q24, this confirms the high involvement of this region in prostate tumours from men of African ancestry. Mortality by prostate cancer is higher in African Caribbean men than in French Caucasian men. Specificities of the former could be explained by genomic -events linked with key genes such as DNA- damage pathway genes PARP1, CDK12, and the oncogenic long non coding RNA gene PVT1 at the 8q24 prostate cancer susceptibility locus” [22].

Firouz Daneshgari et al. [23]: “In natural history of DBD, we have observed that morphological- functional manifestations of DBD in STZ-induced DM are time-dependent. Bladder hypertrophy and remodeling, increased contractility and associated neurogenic -changes occur soon after the onset of DM . While the drop of peak voiding pressure in the cystometric- measure, develop only at a later stage of DM. The time-dependent alterations of DBD served as the basis for our ‘temporal hypothesis’ of DBD with mixed clinical manifestations, in which we propose that DM causes the bladder to undergo 2 phases of alterations via two main mechanisms: In the early- phase, hyper-glycemia-induced osmotic polyuria is the main mechanistic factor that causes compensatory bladder hypertrophy and associated myogenic and neurogenic alterations. later phase, accumulation of oxidative- stress products during prolonged hyperglycemia causes decompensation of the bladder tissues and function.

Unlike most other organs affected by D. Mellitus, the bladder faces not only hyperglycemia, but also an exceptionally high volume of urine output. In the experimental models, sucrose-induced diuresis causes rapid and substantial bladder- hypertrophy and increased bladder contractility, capacity and compliance that are similar to those changes observed in the diabetic rats. Those similarities suggest that bladder hypertrophy in diabetic- animals may result from a physically adaptation to increased urine production. Bladder hypertrophy may also initiate the process of the increased oxidative stress. The excess ROS -cause, in turn, DNA strand breaks, activation of poly (ADP-ribose) polymerase PARP and inhibition of glyceraldehyde-3 phosphate dehydrogenase (GAPDH), culminating in the activation of the four damaging pathways.

Numerous studies in the role of oxidative stress on the pathogenesis of diabetic complications in the eye, nervous -system, kidney and cardiovascular system, studies on the direct effect of oxidative stress in the urologic -complications has not yet been investigated in detail. Few studies on its role in erectile -dysfunction and on cystopathy have indicated the importance of oxidative stress in the pathogenesis of urologic diabetic -complications. Using rabbit model of alloxan-induced diabetes, we showed that the decrease in the contractility of the detrusor smooth muscle (DSM) is associated with increased lipid peroxidation products and overour preliminary expression of aldose reductase. Mitochondria are the major source of superoxide, peroxynitrite and hydroxyl radicals in all types of cells. Our data show that treatment of high glucose increases the mitochondrial membrane potential and ROS in cultured human bladder smooth muscle cells (hBSMC), in agreement with the published reports showing that the mitochondrial dysfunction is a key mechanistic step in diabetes complications. Mitochondrial dysfunction reduces the production of ATP, affecting the ability of cross -bridges to cycle during the force generation.

Endogenous antioxidants are able to destroy the ROS and create a balance between antioxidant and free radicals in a normal situation; however, in diabetes the antioxidant defense system is deficient due to the high level of oxidative stress. Intake of the antioxidants, such as vitamin E and α-lipoic acid, which functions as a cofactor in multi-enzyme complexes, have been successfully used to reverse oxidative stress produced by hyperglycemia in human diabetics and in STZ-induced diabetic animal models. An Oral treatment of α-lipoic acid (600 mg / day for 5 weeks) improved neuropathic deficits in diabetic patients with distal symmetric polyneuropathy in a recent clinical trial. Pathophysiology of DBD is multifactorial: it involves alterations in detrusor, nerve, urothelium and urethra. The pathophysiology of DBD is multifactorial, including disturbances of the bladder detrusor, urethra, autonomic nerves, and perhaps the urothelium. Researcher have observed that, upon induction of DM in the rodents by destruction of the pancreatic β-cells with STZ, the bladder and urethra undergo morphometric and functional changes in both myogenic - neurogenic components. Other study has demonstrated the potentially obstructive effects of urethral sphincteric mechanisms in DBD.

In vivo and in vitro experimental studies on DSM from animal models of DM do give evidence for myogenic changes. Studies on the effects of diabetes on detrusor contractility sho decreased and increased force production in rat DSM strips. Contractility of the DSM was decreased in response to stimulation by KCl and carbachol, and the decrease was associated with not only the duration of the hyperglycemic state but also the level of hyperglycemia. Changes in muscarinic -receptor population have also been linked to altered contractility. Unlike the changes in the DSM from an obstructed bladder, we found, using STZ-induced rat diabetic model and an alloxan-induced rabbit model, that there is no change in the myosin isoform composition in the DSM from diabetic animals.

A>regulatory mechanism for smooth muscle contraction is the myosin-mediated regulation via phosphorylation-dephosphorylation of the regulatory myosin light chain (MLC20) by Ca2+-dependent myosin light chain kinase (MLCK) and the myosin light chain phosphatase (MLCP). The MLCP is inactivated by phosphorylation (catalyzed mainly by Rho-kinase) rho-, and also by binding to phosphorylated CPI-17. By lowering the activity of the MLCP, these proteins retain the myosin in the phosphorylated state and maintain the muscle tone in the absence of an elevation of cytosolic Ca2+. Studies performed on DSM from diabetic animals showed overexpression and over-activity of Rho-kinase and CPI- 17 proteins involved in the Ca2+- sensitization in smooth muscle. We also found high level of basal MLC20 phosphorylation in the diabetic- detrusor.

Other important, function of epithelial cells is their ability to sense the changes in their extracellular environment and then communicate these changes to the underlying nervous, connective and muscular tissues. This communication is likely to be very important for tube- and sac-shaped organs such as blood vessels, the gut, bladder, whose normal function can be modulated by stimuli initiated within the epithelium. Though alterations in smooth muscle and nerve innervation have been shown in diabetic patients, there are little information regarding the involvement of the urothelium in the pathophysiology of DBD. Studies using the STZ-induced diabetic rat model, report an increase in urothelium proliferation without an increase in the thickness of the urothelial lining itself. This increase in the proliferation may divert the physiology of the urothelium cells from their normal inter-communication/2-way communication with the underlying bladder tissue, by modifying both urothelial cell -receptor expression and the release of signaling molecules such as neurotransmitters. This in turn could impact/modify the activity in underlying smooth muscle and nerve endings and contribute to the bladder function modification observed in DM. It was reported that urothelial cell prostaglandin- release is impaired, in STZ-DM rats. This might affect the barrier function of the urothelium. Prostaglandins are known to play an important role in the maintenance of musical integrity in the gut. In addition, it has been proposed that the common occurrence of urinary tract infections seen in DM and attributed in part to the bladder stasis seen in the pathology, may be as a result of altered expression of adherence receptors for bacteria by urothelial cells.

Abnormalities in bladder- urothelium could impact the LUT function by altering release of mediators as excitability of sensory fibers in the bladder. Many urothelial functions may be altered in diabetes, defects in urothelial cells may underlie, in part, changes such as detrusor instability and/or changes in bladder capacity. The urothelium is an active participant in the normal function of bladder and exists as an integral part of a sensory web, in which it communicates the degree of bladder filling to the underlying nervous and muscular tissues and affects their functions. This communication is made possible by the input / output pathways of the urothelium, which allow it to respond to its chemical and physical environment and to engage in multi-directional communication with neighboring cells in sub adjacent tissues. Defects in urothelial expression of the receptors or aberrant release of mediators may contribute to diabetes-associated bladder complications.

The neuronal control bladder function involves a very complex interaction between the autonomic and somatic afferent and efferent pathways. One group reported an association of DBD with autonomic neuropathy detected by sympathetic skin response in diabetic patients. Steers et al showed significant abnormalities in the afferent pathways innervating the bladder in STZ induced diabetic rats. Adult rats that was treated with capsaicin, a C-fiber afferent neurotoxin, exhibit a number of similarities to diabetic rats. Since the capsaicin is known to affect predominately small myelinated and unmyelinated afferents, it is tempting to speculate that DM affects a similar afferent neuron population. It has been suggested that DBD is initiated by a neuropathy in the efferent limb of the micturition reflex.

Neurotrophic factors derived from target -tissues can support the growth and survival of peripheral neurons. Rats with STZinduced DM, 12 weeks after induction, showed significantly decreased levels of nerve growth factor NGF, a the neurotrophic, in the bladder and in L6 to the S1 dorsal root ganglia, which contain bladder afferent neurons. Reports that diabetic rodents show a loss of neurotrophic support to peripheral nerves have prompted studies to investigate efficacy of neurotrophic factor supplementation on nerve disorders of diabetic rats. The use of an exogenous neurotrophic factors as a therapy is limited by the need for non-oral delivery, the fiber selectivity of individual neurotrophies, limited delivery to the nervous system and concerns about harmful systemic-actions of growth factors” [23].

Montalbetti N et al. [24]: “Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic voiding disorder that presents with pain in the urinary bladder and surrounding pelvic region. Evidence suggests that: an increase in the permeability of the urothelium, the epithelial barrier that lines the interior of the bladder, contributes to the symptoms of IC/BPS. To examine the consequence of increased urothelial permeability on pelvic pain and afferent excitability, we overexpressed in the urothelium claudin 2 (Cldn2), a tight junction (TJ)-associated protein whose message is significantly upregulated in biopsies of IC/BPS patients. In presence of bladder-derived pain, rats overexpressing Cldn2 showed a hypersensitivity to von Frey filaments applied to the pelvic region. Overexpression of Cldn2 increased the expression of c-Fos and promoted the activation of ERK1/2 in spinal cord segments receiving bladder input, which we conceive is the result of noxious stimulation of afferent pathways. To determine whether the mechanical allodynia observed in rats with reduced urothelial barrier function results from altered afferent activity, we examined the firing of acutely isolated bladder sensory neurons. In patchclamp recordings, about 30% of the bladder sensory neurons from rats transduced with Cldn2, but not controls transduced with GFP, displayed spontaneous activity. Bladder sensory neurons with tetrodotoxin-sensitive (TTX-S) action potentials from rats transduced with Cldn2 showed hyperexcitability in response to suprathreshold electrical stimulation. These findings suggest that as a result of a leaky urothelium, the diffusion of urinary solutes through the urothelial barrier sensitizes bladders afferents, promoting voiding at low filling volumes and pain” [24].

Helen L. Nicholson et al. [25]: The aim of this review- study is to examine all urethral strictures and stenoses subsequent to treatment for prostate cancer, including radical prostatectomy (RP), radiotherapy, high intensity focused ultrasound (HIFU) and cryotherapy. The overall majority respond to the endoscopic treatment, including dilatation, direct visual internal urethrotomy (DVIU) or bladder neck incision (BNI). There are adjunct treatments to endoscopic management, including injections of corticosteroids and mitomycin- C (MMC) and urethral stents medical devices, which remain controversial and are not currently mainstay of treatment. Recalcitrant strictures are most commonly managed with urethroplasty, while recalcitrant stenosis is relatively rare yet almost always associated with bother some urinary incontinence, requiring bladder neck reconstruction and subsequent artificial urinary sphincter implantation, or urinary diversion for the devastated outlet.” [25].

Zhigang Zhao et al. [26]: “Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) present significant economic costs and severe impact on the quality of life of diagnosed patients. Prevalence: between 2.2% and 13.8%. Symptoms of this condition include chronic pain, voiding symptoms, pelvic, sexual and psychosocial disturbances, among others. Until To date, no single specific therapy is effective in all the patients. The major reason for this is that the patients with CP/CPPS are not a homogenous group with a single disease process who respond in the same way to specific medications, but rather a heterogeneous group of unique individuals with widely different etiological mechanisms, disease characteristics, symptom complexes, and progression trajectories. It is rational to evaluate CP/CPPS patients as individuals with differing clinical phenotypes. No- validated predictors /biomarkers are currently available that help classify those patients in a way that could guide the therapy. In 2009, Shoskes developed a 6-point clinical phenotyping system called UPOINT to classify the patients with CPPS and interstitial cystitis and subsequently direct appropriate therapy.

The clinical- domains are urinary symptoms, psychosocial dysfunction, organ specific findings, infection, neurological/systemic, and tenderness of muscles. Each domain has been clinical ly- defined, linked to the specific mechanisms of symptom production or propagation, and associated with the specific therapy. This kind of phenotype is qualitative, with each domain scored as yes or no. The major finding of the first UPOINT retrospective study was the strong correlation between the number of UPOINT positive domains and the NIH-CPSI total- score in each patient, which was further verified by other studies. Recently, the UPOINT-guided multimodal therapy has been shown to significantly improve symptoms. It is widely acknowledged that CP-CPPS is associated with significant sexual dysfunction. Erectile dysfunction (ED) is the most investigated sexual dysfunction in patients with CP/ CPPS. The reported ED prevalence findings for CP/CPPS sufferers ranged from 15.0% - 48.3%. However, the original UPOINT phenotype system did not include a domain for sexual dysfunction or ED. A Swedish study recently showed that the number of positive UPOINT domains was not correlated with ED severity in CP/CPPS patients. The impact of adding a sexual- dysfunction or ED domain to the UPOINT system on patients’ symptoms is also conflicting.

For international validation and adoption of this novel UPOINT algorithm a prospective study was conducted in a Chinese- cohort of males with CP/CPPS. We sought to determine the clinical- phenotype of those Chinese CP/CPPS patients using the UPOINT classification system and assessed the frequency of individual domains and their effect on symptom severity and m the erectile function. We aimed to further investigate the impact of adding an ED domain to create a modified UPOINT phenotyping system on symptom severity of CP/CPPS patients. The utility of the UPOINT classification scheme in discriminating clinical phenotypes has been validated in the Chinese cohort of CP/CPPS, with the number of + domains shown to be strongly correlate with the duration and severity of prostatitis symptoms and with the ED symptoms. Adding an ED domain restored a significant association between the number of a modified UPOINT domains and the NIH-CPSI scores. Our prospective analyses demonstrate that ED is an important component of the clinical phenotype of CP/CPPS, the addition of an ED domain to the UPOINT- system adds a value to the clinical assessment of the CP/CPPS symptom severity. This results here support the utility of using ED as an independent UPOINT domain” [26].

Kim Moon et al. [27]: “Acute ethanol intoxication is a predisposing factor for urinary retention induced by BPH. The mechanisms of ethanol‐induced urinary retention are an alcohol‐induced diuresis and the α‐sympathomimetic effect of ethanol itself, along with depression of the CNS. Ethanol‐induced congestion of the prostate and the prostatic urethra could also obstruct outflow. After ingestion, ethanol is metabolized sequentially to acetaldehyde, acetate, CO2 and water. The negligible blood concentration of acetaldehyde found after the ingestion of alcohol in most Caucasian subjects under normal conditions suggests that acetaldehyde is of interest only when acetaldehyde dehydrogenase (ALDH2) is inhibited. About half of Oriental subjects have a deficiency of mitochondrial ALDH2, resulting in increasing acetaldehyde levels after ethanol intoxication. Ethanol seems to inhibit smooth muscle contraction but the effects of ethanol and acetaldehyde on the responses of the bladder have not been assessed.

Acute ethanol intoxication causes urinary retention in patients with BPH. In animals’ ethanol significantly, impaired detrusor contractility in vivo- in vitro. The primary enzymatic steps in ethanol metabolism to acetaldehyde, acetate, CO2 and water have been known for many decades. Alcohol‐related flushing, which occurs in about half of Oriental subjects after ingestion of alcohol, is caused by deficient activity of mitochondrial ALDH2, resulting in increased acetaldehyde levels. Acetaldehyde is the principal metabolic by‐product of ethanol metabolism causing cytotoxicity, and may be limited by administering vitamin C. In an animal study, chronic acetaldehyde exposure impaired the inotropic response to membrane depolarization in endothelium‐denuded preparations of rat aorta, resulting in depressed responsiveness; acute acetaldehyde exposure significantly reduced both noradrenalineand Kcl‐induced contractile responses , but low concentrations of acetaldehyde enhanced the spontaneous phasic contractile activity .In Normally circumstances, the acetaldehyde produced as a result of ethanol metabolism is rapidly oxidized to acetate by aldehyde dehydrogenase, and other microsomal enzymes . There are several conditions in which the plasma concentration of acetaldehyde is significantly increased after ethanol ingestion, e.g. alcoholism or subjects undergoing therapy with oral hypo glycaemic agents. Therefore, after alcohol ingestion, acetaldehyde may affect bladder detrusor contractility, although the effects of acetaldehyde on bladder detrusor muscle remain uncertain.

The present study investigated the effects of acetaldehyde on isolated rat bladder muscle, thus eliminating the effects of innervation. Acetaldehyde increased bethanechol‐induced bladder contraction when applied acutely, although chronic exposure to ethanol and acetaldehyde alone decreased the contractility of the bladder. In the guinea‐pig, atropine did not prevent acetaldehyde‐induced bronchoconstriction, and acetaldehyde has a bronchospastic action via histamine release. In the present study, as acetaldehyde‐induced bladder contraction was also completely blocked by the H1 antagonist, bladder contraction was probably enhanced by the release of histamine “[28].

Bayrak O et al. [29]: “To demonstrate the effects of intravesical ozone treatment on inflammation and epithelial cell damage in chemical cystitis animal model. A total of 30 New Zealand rabbits were divided into 6 groups. Cystitis was conducted with a transurethral intra-vesical HCL- instillation on the subjects in Groups IA, IB, IIA, and IIB. Group IA-IB subjects was transurethral administered intravesical ozone- therapy twice a week, Group IIA-IIB subjects were only given an intravesical isotonic NaCl instillation. Group IIIA-IIIB subjects were administered intravesical isotonic NaCl instillation without conducting chemical cystitis in order to create the same stress. Following a 3-week (early period) and 6-week (late period) therapy, the rabbits were sacrificed, and his to-pathologic investigations tests were carried out in order to demonstrate changes in the urinary bladder.

We observed that the basal -membrane and the mucosal integrity were maintained, the inflammatory cells were suppressed in Group IA-IB (Early and late period), which received ozone therapy. However, it was observed that the mucosal integrity was spoiled, numerous inflammatory cells were accumulated in Group IIA-IIB, which was administered isotonic NaCl. Due to its low cost and minimal side effects; ozone therapy could be a new therapeutic approach in the treatment of interstitial cystitis.” [29]

According Subhash Haldar et al. [30]: “Cystitis can be: acute or chronic, and severity can range from mild discomfort in the lower abdomen to severe life-threatening hemorrhage. The many etiologies of cystitis: infection, radiation, chemical, mechanical, interstitial cystitis/chronic pelvic pain syndrome, and several conditions that can masquerade as cystitis. Cystitis can be classified: infectious versus non-infectious” [30].

Response rates in these studies range from about 70- 95%. Perez-Marrero et al. performed randomized- placebocontrolled crossover clinical trial in about 33 patients and assessment based on urodynamics and symptoms. Compared to the placebo, DMSO showed a higher objective (35%vs.93%) and subjective (18%vs.53%) improvement. Peeker et al. performed a randomized -double-blind crossover clinical study comparing DMSO to intravesical BCG in 21 patients. Each group underwent 6 weekly instillations and crossed-over to other treatment if no improvement was noted. The Patients were assessed with a symptom questionnaire (VAS pain scale and voiding diaries.) No improvement in any of the outcome measures were seen following BCG: the study was likely to be underpowered. DMSO resulted in significant reductions in pain and the urinary frequency parameter.

Ghoniem et al. utilized a DMSO cocktail: premixed 50mL solution of 50% DMSO, 40mg methylprednisolone and 5,000 units of heparin sulfate in 25 patients. 6 instillations (the first performed under general anesthesia after hydrodistension) were administered at weekly- intervals. Outcome measures were not well defined, with 92% achieving an initial remission for an average of 8 months. 9 patients (36%) had one or more relapses and required further instillations or oral therapy. Lim et al. reported long-term outcomes following a DMSO cocktailinstillation (50mL of 50% DMSO, 100mg hydrocortisone, 0.25% bupivacaine and 5,000 units of heparin). Mean follow-up of about 55 patients was at 4.65 years and the overall improvement as assessed on ICSI/ICPI and VAS a pain score was: 23-47%. At longterm follow-up 34% were cured after 1 course, 22% required oral medication, 24% had a DMSO top-up; the remainder went on to receive the other treatments. Anaesthetic bladder capacity about ≤500mL was associated to a lower response rate.

Heparin and lidocaine: Heparin are a sulfonated- GAG with theoretical action of replenishing urothelial GAG layer. Heparin acts as anti-inflammatory molecule inhibits the fibroblast proliferation and promotes angiogenesis and the smooth muscle cell proliferation. Lidocaine is a topic an aesthetic- drug and is used as a single-agent instillation or, in combination with the heparin. It is given in various formulations /concentrations, usually in combination with alkalizing- agent (sodium bicarbonate) to avoid the ionization within urine and in order to better penetrate the urothelium.

Single-agent heparin studies have shown modest benefit in patients with BPS/IC. Parsons et al. reported on about 48 patients undergoing instillation with 10,000U of heparin 3 times a week for 3 months. 56 % attained a good clinical remission. Single alkalized lidocaine (200mg lidocaine plus 8.4% sodium bicarbonate, 10mL) was reported by the author Nickel et al. in a randomized, doubleblind placebo-controlled industry sponsored study of about 102 patients. Instillations occurred daily for about 5- consecutive days. The primary clinical outcome was based on the Global Response Assessment. On day eight, patients in lidocaine group had significantly higher improvement than the placebo (30%vs.10%, P=0.012); this improvement was still present at day 15 (but not statistically significant 24%vs.12%, P=0.102). 82 patients elected to continue the open-label phase of the clinical study and underwent a further 5-day course of the lidocaine treatment with similar rates of the improvement.

To improve the response rates, multi-agent therapy with: heparin and alkalized lidocaine has been studied. Parsons et al. have studied the efficacy of heparin and alkalized lidocaine in about 82 patients. Group 1 received about 40,000 units of heparin, 8mL of 1% lidocaine and 3mL of 8.4% sodium bicarbonate. Group 2 received increased concentration of lidocaine (8mL of 2% lidocaine). An Immediate relief of the pain and frequency after 1 instillation was higher in group 2 than the group 1 (94%vs.75%; P<0.01). 20 patients in group 2 underwent a further 6 instillations over 2 weeks, 80% showed: symptom relief persisting at least for 48 hours after last treatment. The Improved duration effect was showed by Nomiya et al. in a clinical study of 32 patients undergoing 12 weekly instillations of 20,000 units heparin, 5mL 4% lidocaine and 25mL 7% sodium bicarbonate. On GRA, 76% responded at the end of treatment, responses of 90% at 1 month, 46% at 2 months and 16% at 6 months- following the treatment.

Pentosan polysulfate sodium (PPS): PPS is the only oral -agent approved for BPS/IC by FDA org. It is an oral -eparinoid molecule and likely exerts its effect for treatment of BPS/IC by restoring the GAG layer. It inhibits histamine release by the mast cells and reduces the intracellular calcium- ion levels in the bladder. Main disadvantage is the low urine concentrations achieved, resulting in a lag -time of up to the 6 months before clinical improvement is observed. Intravesical therapy has theoretical advantage of achieving more rapid response to PPS treatment.

Davis et al, randomized, double-blind controlled study comparing oral PPS and intravesical PPS to oral- PPS and intravesical placebo in about 41 patients. Instillations occurred 2 times weekly for 6 weeks whilst oral- therapy was given for a total of 18 weeks. At the end of the study period, the treatment group were shown to have a statistically greater reduction in ICSI/ICPI scores compared to placebo (46% reduction vs.24% reduction; P=0.04). Health-related quality of life-domains also showed a statistically greater improvement in the treatment group.

Sodium hyaluronate (HA): Rationale is to replenish deficiencies in the GAG- layer (other biological activities including enhancement of connective tissue healing and inhibition of the leukocyte migration and aggregation may contribute to its action in BPS/IC patients. It comes as a 40mg dose in 50mL solution). Most studies use a treatment regimen consisting of 4 weekly instillations followed by monthly- therapy until the symptoms have been resolved. Riedl et al. prospectively studied the efficacy of HA in 126 patients as first line therapy. Weekly instillations of HA were given until the patients were significantly clinically improved or symptom free. The Assessment was based on a non-standardized questionnaire (using a VAS symptom- score, impact on quality of life question and willingness to undergo repeat the instillation therapy). This was administered at baseline and at a mean of 6 months after the last HA- instillation. The average number of instillations was 12.2.

About 85% of patients reported symptom improvement (≥2 VAS units); 55% had no or minimal bladder symptoms after the therapy. 84% reported a before rest improved quality of life (although this was not objectively quantified) and 86% would undergo repeat HA treatment if necessary. 34% had a recurrence of symptoms and required further instillations- the duration of the effect before a restarting treatment was not stated. The same group then published long-term follow-up data of 48/70 patients from this cohort who were contacted at a mean follow-up of 5 years. 50% had sustained improvement and did not require any further treatment. 41% continued with an intermittent HA instillation therapy with or without oral pentosan polysulfide.

A smaller case- series have reported an improvement rates with HA instillation of between: 30-85% with varying the follow-up times and instruments used to assess outcomes. Shao et al. in a prospective open-label controlled clinical trial in 47 patients examining the use of HA after hydro-distention. Patients with functional bladder- capacities < 200mL underwent hydrodistension followed by a treatment with either HA (n=20) or a heparin/lidocaine cocktail (n=16). Treatments occurred weekly for 4 weeks, then monthly for a further 2 months. 7 patients served as ‘controls’ undergoing only hydrodistension. Assessment was based on urinary frequency, bladder capacity, and VAS pain- score at baseline and 3, 6 and 9 months following hydro-distension. At 6 months, 78% in the HA- group and 33% in the heparin group had improvement in their symptom’s vs 9% in the hydrodistension group. At 9 months, improvement was sustained (but diminished) in the HA group but not in the heparin group.

There were no adverse- effects related to HA or heparin however two patients had bladder- rupture during hydrodistension. Gulpinar et al. reported the use of electromotive drug administration (EMDA) to improve the efficacy of HA treatment. EMDA increases the tissue uptake of drug compared with a passive diffusion. 31 patients were randomized to instillation of the HA alone (n=15) or HA with EMDA with placement of suprapubic electrodes (n=16). Patients were not blinded to the treatment allocation. Follow-up was at 1, 6, 12, 24 months. Both groups had statistically- significant improvement in all the parameters assessed (urinary frequency, nocturia, VAS- pain, How to cite this article: Mauro L, Naseer A, Behzad N A, Ghulam R M, Kausar R K, et all. Receptor Pharmacology and Other Relevant Factors in Lower Urinary Tract Pathology Under a Functional and Toxicological Approach: Instrument to Better Manage Antimicrobials Therapy. J of Pharmacol & Clin Res. 2018; 6(4): 555694. DOI: 10.19080/JPCR.2018.06.555694. 0022 voided- volume, ICSI/ICPI and global response assessment) at 6 - 12 months; the percentage of responders was higher in the EMDA group than in HA alone group (69% vs. 58%, P=0.042). By 24 months, only voiding frequency and VAS- pain scores were still significantly improved from the baseline in both groups. 2 industry-sponsored randomized, placebo-controlled clinical trials of HA were completed in 2003/04. Both trials showed a non-significant improvement in the treatment group compared to placebo and remain unpublished in the peer-reviewed literature.

Chondroitin sulfate (CS): CS is a component of the GAG layer and has been shown to be deficient in patients with BPS/IC. As its role in the GAG layer, CS inhibit the recruitment of inflammatory cells to the deep layers of bladder wall. Nordling et al. conducted a multi-center, prospective observe. trial of 40mL of 0.2% CS in 286 patients with chronic -cystitis (51% were BPS/IC patients). Instillations occurred weekly for the first 4-6 weeks, then monthly until 12 weeks (with a maximum of 8 instillations). Outcome measures from baseline to end of study included a change in daytime and nocturnal frequency, urgency and pain- scores and a global response assessment. Overall, statistically significant changes were seen in all parameters and this was also seen in a subgroup analysis of the BPS/IC patients. GRA response was 76%.

Nickel et al: multi-center, prospective observational -study of 20mL 2% CS. 53 patients underwent 6 weekly instillations followed by a further 4 instillations at monthly intervals. Global response was assessed at week 10, 24 (with rates of 47% and 60%. At week 24, ICSI and ICPI scores significantly decreased as did VAS pain and urgency scores) randomized, double-blind, inactive- vehicle control clinical trial of 20mL 2% CS. 98 patients underwent eight weekly instillations, then monthly treatments to 10. No statistically significantly results were obtained with respect to the GRA (treatment group 38% vs. the control 31%) or based on changes in ICSI/ICPI scores/frequency/urgency/voided volume or VAS- pain scores. The study was under-powered and based on these results (would require a total of 1,500 patients to be adequately powered to show a difference in outcomes between the 2 groups), the author’s conclusion was that single-agent therapy with CS could not be supported.

Sodium hyaluronate and chondroitin sulfate (HA-CS): reduce the production of pro-inflammatory cytokines, reduce the urothelial permeability, facilitate the repair of protective GAG- layer. HA-CS is available as a 50mL preparation containing 1.6% HA and 2% CS with calcium chloride in H20. 3 small case series with 63 patients have been published assessing treatment response to HA-CS. Instillations occurred weekly for a period of 4-20 weeks, further biweekly/monthly instillations until treatment response was assessed. All studies reported significant changes from baseline in ICSI/ICPI scores. Cervigni et al showed significant changes from baseline in VAS pain-urgency scores. Cervigni et al. presented at ICS 2014 an IBSA funded study comparing 13 weekly instillations of Ialuril with DMSO in a 2:1 random- allocation with 110 subjects with ESSIC criteria for BPS. The baseline demographics, VAS- pain scores were similar. The results were: VAS score reduction of -39 (SD 25) vs. -31 (SD 26) points for ialuril, DMSO respectively. Response at 6 months defined as a>30% reduction of the VAS from the baseline was 73% vs. 58% for ialuril and DMSO respectively. Adverse- events were higher in the DMSO group at 31% vs. 15%. There were 7 dropouts overall and were evenly divided.

Oxychlorosene sodium (OS): OS is a stabilized organicderivative of hypochlorous -acid. It has been used as antibacterial extensively in general surgery, particularly in the irrigation of wounds. Its use in the BPS/IC population stemmed from its role in TBC cystitis, when infection was thought to be an inciting event in the BPS/IC cascade. The mechanism of action of OS in BPS/IC is unclear but some have hypothesized that it may act by desensitizing or degranulating bladder nociceptive nerve endings. Initial cases published in the 1950 -70’s provided some encouraging results, with response rates of 70-80%. OS has been designated as a historical treatment in various reviews of intra-vesical therapy for BPS/IC. The authors are involved in a multi-center, randomized, single-blind controlled clinical- trial assessing the efficacy of a single- instillation 0.4% OS under general anesthesia compared to hydro-distension.

Botulinum toxin A: potent neurotoxin, inhibit the release of acetylcholine and other neurotransmitters from both afferent and efferent nerve terminals as well as ATP from the urothelium. Chronic inflammation, apoptotic- signaling properties is significantly reduced following intra-vesical botulinum toxin A injections, but only after repeated injections. The recently amended AUA- guidelines for the treatment of BPS/IC have moved botulinum toxin A from 5th to first 4th line therapeutic treatment. Most clinical studies of botulinum toxin A use on botulinum toxin A. A number of case series with 11-16 patients each, showed that intravesical injections of 100-200 units of Botox resulted in high response rate 71-100%. Significant reductions in VAS- pain scores, urinary daytime, night-time frequency was seen at 3 months follow-up. These clinical studies varied in the dose injected, the number of injections and the site of injection: trigonal vs. separational.

Kuo et al: performed a multi-center, randomized, doubleblind placebo-controlled clinical- trial of Botox in BPS/IC patient’s refractory to the conventional treatment. 40 patients underwent suburothelia injections of 100 units Botox and hydrodistension whilst 20 control-l patients underwent a normal saline injection and hydrodistension. At 8 weeks post-treatment, overall success was greater in Botox group compared to the control group (63%vs.15%, P=0.028). VAS pain scores (−2.6vs.−0.9, P=0.021) and cysto-metric capacity (+67.8vs.−45.4, P=0.02) were significantly changed in the Botox group compared to placebo. Adverse- events: dysuria (16/40 Botox, 1/20 control), urinary tract infection (2 Botox), urinary retention (1 Botox) and hematuria (1 Botox) were all greater in Botox group. In a prospective series of 44 patients undergoing 6 monthly Botox injections, Lee and Kuo reported that Botox was not beneficial in ulcer type BPS/IC patients.

Manning et al: reported about the use of botulinum toxin A. This was a multi-center, randomized, double-blind placebocontrolled clinical trial in 54 patients. Disport 500U suburothelia injections plus hydrodistension was compared to a normal saline SOL. injection plus hydrodistension. O’Leary Sant overall scores were improved in the both groups at 3 months with no statistically significantly difference seen between the 2 groups. Only the OLSproblem index improved in Dysport group (P=0.04). This study found that post-treatment UTI was a confounder and that when the 12 patients were excluded from the analysis, the OLS overall score and OLS-symptom index were significantly improved in the Dysport group. The authors concluded: Dysport may be beneficial in a small number of patients and that patients without posttreatment UTI presented a better response.

Capsaicin and the resiniferous toxin are C-fiber afferent neurotoxins. Considered as candidates for BPS/IC based on their theoretical ability to alleviate bladder symptoms by desensitizing bladder afferents. Whilst the clinical- efficacy for resiniferous toxin was initially demonstrated in a number of small clinical studies, these results have not been confirmed in placebocontrolled clinical studies. They are currently not- recommended for intravesical use in BPS/IC patients. Bacillus Calmette-Guerin (BCG), an immune-modulatory agent used for intravesical treatment of bladder cancer. An initial open label study provided promising results, BUT a randomized double-blind study demonstrated no clinical benefit. Adverse events may be serious, so BCG is not recommended for use in BPS/IC patients. Liposomes are phospholipid vesicles, when applied to cell -walls they create a molecular film. they may be able to restore the GAG layer. A small pilot -study has shown A significant improvement in frequency, nocturia, and pain in 24 patients undergoing intra-vesical liposomal instillations compared to oral PPS. A randomized, placebo-controlled clinical trial is currently underway assessing the efficacy of two doses of intravesical liposomal therapy compared to placebo [44].

Sudhindra Jayasimha: “Nanotechnology has revolutionized our approach to the medical diagnostics / therapeutics and has spanned an entirely new branch of science research. This review studies addresses the potential applications of the Nano-technology in Urology filed. The developments in urology- diagnostics include novel techniques of imaging of genitourinary malignancies, prostate-specific antigen measurement, early detection of mutations that are diagnostic for polycystic kidney disease. The potential- applications of nanotechnology are in targeted therapy of genitourinary malignancies, erectile dysfunction, overactive bladder, bladder reconstruction, construction of artificial kidneys and biodegradable stents, in robotic- surgery.

Treatment of overactive bladder/interstitial cystitis: Intravesical therapy, while overcoming side effects of anticholinergics such as dry mouth and constipation, provides higher local drug concentrations / efficacy. Systemic toxicity is limited as the urothelium of the bladder is the most impermeable epithelial- barrier of the body. Weekly intravesical empty liposomes (80 mg in 40 ml water) have been shown to ameliorate the symptoms of interstitial- cystitis with decreased frequency, nocturia, and O’Leary-Sant symptom score. In this aspect, liposome therapy was found to be superior to oral pentosan polysulfate.

Liposomes may also be used as a vector for the botulinum neurotoxin. This improves the efficacy of the drug as uptake is better, the degradation by proteases is prevented. The need for an intravesical injections can be circumvented as the efficacy remains the same which was demonstrated in acetic acid rat- model. Imaging of interstitial cystitis is also aided by Nano-technology as liposomes and fluorescent Nano-particles bind to bladder lesions of interstitial cystitis which may be assessed by NIR- imaging of bladder” [45].

Martino Maria Zacchè et al. [45]: “Novel targeted DDSs was recently developed to prolong the effect of drugs in bladder. This has been possible with introduction of Nano-technology in the field of drug -delivery. Substances are loaded within Nanoparticles. This holds a high potential in improving the therapeutic value of different drugs- Molecules by increasing bioavailability, solubility, and retention time. Nano-carriers can deliver drugs molecules to site-specific targets. They can be formulated from materials like lipids, polymers, proteins, and metals. Liposomes are phospholipid concentric /bilayer Nano -spheres mimicking human cell walls. They allow the delivery of both the lipophilic drugs molecules such as capsaicin and hydrophilic drugs such as botulinum toxin. Clathrin-mediated endocytosis (is their route of entry into the urothelium).

Intra-vesical administration of the liposomes alone can enhance resistance to irritant penetration as shown in ratmodel with hyperactive- bladder. Clinical Studies showed that intravesical liposomes are safe and have similar efficacy to one of the most effective FDA-approved pharmacological treatments for IC as an oral pentosan polysulfide (PP). (Empty liposomes have been shown to be effective as potential treatment of IC). This related to their ability to form a protective- lipid film on urothelial surface. In a study, intravesical instillation of PP encapsulated in liposomes was effective in refractory IC pat. Studies with bigger number and placebo groups are warranted.

Liposomal-vesicles enhance the therapeutic index of chemotherapeutic agents and represent a promising approach for cancer treatment. A Phase II clinical trial Study is evaluating temperaturesensitive liposomes plus local hyper-thermic in patients with recurrent chest wall breast cancer. Encouraging results could lead to explore this approach in different clinical setting like BC. Other Nano-carriers are solid lipid nanoparticles, protein nanoparticles with targeted ligands grafted on the surface, branched polymeric den-dimers, muco-adhesive bio-polymers (chitosan) or synthetic polymers, magnetic particles, gold Nano-shells, and in situ gelling systems.

Polymeric hydrogels

A Novel approach is the use of hydrogels as depot formulations on the bladder- walls. This provides longer exposure of the urinary tract tissue to existing drugs, as compared to standard intravesical instillation, as they remain attached to the bladder wall even after urine voiding- fases.

Thermosensitive hydrogels

These are aqueous solutions of poly (ethylene glycol-b- [dl-lactic acid-co-glycolic acid]-b-ethylene glycol) triblock copolymers that form a free-flowing solution at room temperature and become a viscous gel at body temperature of 37 °C. (it is fluid when cold and a gel at body temperature). Following the instillation, gel solidifies and acts as sustained drug release depot in situ. When the gel is in contact with urine, it dissolves and gradually releases the drug over a period of 6/8 hours. Thigel slowly excreted from the bladder during urination. It is 100% biocompatible and harmless to the body.

A Phase I/II clinical trial was completed in Israel exploring the feasibility-tolerability- safety of 200 units of onabotulinumtoxin. A premixed with chilled 40mL of TCGel®. Fifteen patients with IC were enrolled in the clinical trial and received a single instillation. Follow-up was at weeks 2, 6, 12 post-instillations. The efficacy outcome measures included IC- Symptom Index (ICSI) and IC Problem Index (ICPI). A reduction in the ICSI and ICPI was observed since week 2 and was also apparent at week 12. No serious drug-related adverse events were reported. Clinical trials are looking to the intravesical instillation of mitomycin C (MMC) mixed with TCGel® in patients with non-muscle-invasive BC (Optimized Instillation of Mitomycin for bladder cancer treatment [OPTIMA] study).

Preclinical results demonstrated:

a) Levels of MMC in the bladder 2 hours and 6 hours following instillation were over tenfold higher as compared to drug alone (same total dosage).

b) Levels of MMC in the urine were higher for a longer period of time compared to drug alone.

c) Levels of MMC in the plasma were low: confirming safety of the treatment.

For intra-vesical chemo-therapy, hydrophobic anticancer drugs offer a distinct advantage of greater permeability through the urothelium as compared to hydrophilic drugs. This allows longer retention of therapeutic doses within the bladder tissue even after the instilled solution is washed- out after voiding. Loading the hydrophobic drugs into carriers for sustained IDD is viewed as one of the most promising strategies to ensure continuous presence of drug in the bladder with fewer or no intermittent catheterization. Muco-adhesive nanogels have been recently evaluated in porcine urinary bladder and could be promising candidate for intra-vesical delivery of hydrophobic drugs in BC therapy.

Intra-vesical instillation therapy has potential benefits including high drug concentration at the bladder and reduced systemic exposure which minimizes systemic- toxicity and side effects compared to oral medications. But repeated instillations are often required to extend the drug exposure, and this lowers the compliance. Indwelling intravesical devices are physical devices that can be inserted and remain in the bladder. The drug is then released from the device in a controlled and extended manner. The device can be either biodegradable or non-degradable. The former eliminates the device removal step but can provoke debris that might lead to voiding difficulties.

A reservoir-based device constructed of a completely biodegradable elastomer supplying ciprofloxacin-HCl has been evaluated in vitro and showed functionality and stability. Biodegradable devices have also been studied for IDD of antimuscarinics as this could represent an alternative to oral treatment for OAB. In vitro studies in a porcine bladder- model showed effectiveness of tropism chloride (TrCl) when loaded onto degradable poly(lactide-co-glycoside)-based polymer carriers. Lipid-based intravesical DDSs were loaded with TrCl and showed a drug- release ranging from several days up to weeks. Trials with nondegradable indwelling devices first evaluated an intravesical pump called UROS. The device was tested in Phase I/II trials.

A nonbiodegradable device, Lidocaine Releasing Intravesical System has been deemed for intravesical delivery of lidocaine. It has a double design: one tube contains solid lidocaine hydrochloride minitablets, enabling a higher dose of drug than if a solution was used, the other lumen contains nickel titanium wire, which adopts a “pretzel” conformation once inside the bladder, preventing it from being accidentally voided. It is retained in the bladder with minimal- discomfort, allowing release of lidocaine for a sustained period. A silicone container absorbs urine to dissolve the lidocaine contents, whereas the osmotic pressure created forces the solution out of the container through a small orifice in a controlled release over 14 days. Promising results were achieved when the device was tried in a rabbit- model. lidocaine concentration in the bladder tissue was >0.1μg/g during the 3-day period of device release, while a single instillation yielded immeasurable amounts within 24 hours.

Phase I safety assessment study in healthy- volunteers. An empty device was inserted into the bladder of 7 women, while 3 women underwent cystoscopy without placement of the device. Tolerability was assessed using visual analog scales for bladder sensation and voiding behavior, which revealed that changes from baseline were similar between groups. A Phase Ib cohort study in 16 women with moderate-to-severe IC followed. Subjects received LiRIS® 200mg or LiRIS® 650mg for 2 weeks. There was a significant improvement in bladder pain, urinary urgency, and voiding frequency.

Cystoscopy findings also improved on day 14 (day of removal) compared with day 1. Most strikingly, of the 6 patients who were noted to have Hanner’s lesion on cystoscopy insertion, 5 demonstrated complete resolution 14 days later. Global response assessment showed an overall responder rate of 64% at day 14 and a sustained overall responder rate of 64% 2 weeks later. Extended follow-up suggests that the reduction in pain was maintained for several months after the device was removed. Expanded Phase II/III clinical trials are now underway. Potentially, other therapeutic agents could be delivered by the device for the treatment of other bladder disorders.

Encapsulated DDS

There are pilot data showing the feasibility of loading an antibiotic into a non-cell-toxic microcapsule that can both penetrate bladder cells and provide slow release of the drug that retains its bactericidal properties. This system has been developed for the delivery of high doses of antibiotic to treat recalcitrant UTIs. The capsules have been prepared with coaxial electrohydrodynamic forming technology, which has shown considerable promise for the production of fibers and particles at the micro- and nanoscale. Polymethyl-silsesquioxane has showed a good biocompatibility, physiological inertness has been inserted in the capsules together with gentamicin. In an in vitro assay, the capsules were able to kill Enterococcus faecalis, the most common uropathies. the capsules were incubated with bladder epithelial cells collected from the urine of patients with UTIs. Successful delivery in bladder cells was demonstrated, but the mechanism is still unknown. High localized doses of antibiotic could be reached by introducing capsules directly into the bladder via a catheter” [46]. According Apul Goel et al. “To evaluate the impact of voiding position on uroflowmetry parameters and to assess its potential clinical implications. We conducted a prospective study from 2013 to 2015 and included men between 18 and 77 years old who were either healthy volunteers with an International Prostate Symptom Score (IPSS)≤7 or men with benign prostate enlargement that were on alpha-blocker medication and had an IPSS<10. Participants underwent uroflowmetry and post-void residual urine (PVRU) measurements twice, once in a sitting position and once in a standing position. The participants were divided into 4 groups based on age (35 years or younger, 36 to 50 years, 51 to 60 years, and older than 60 years).

A total of 740 men with a mean age of 40.35 years were evaluated. There was no significant difference in uroflowmetry parameters until the age of 50 years between the voiding positions. In those older than 50 years, PVRU volume was significantly lower in the sitting position than the standing position, whereas voiding time was significantly higher in the sitting position than the standing position. Other uroflowmetry parameters, including maximal and average urine flow rates, were non-significant. The voiding position plays an important role in the uroflowmetry parameters of elderly men. Voiding in the sitting position was found to be optimal for elderly men, whereas the role of the voiding position in healthy young men could not be determined” [47].

According Ho-Yin Ngai et al. [48]: “Metabolic syndrome (MetS) is a cluster of metabolic abnormalities related to central adiposity / insulin resistance. Its importance is increasingly recognized as it associates with increased risks of metabolic and cardiovascular diseases. These metabolic aberrations of MetS may lead to development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in men. A 26.5%–55.6%

prevalence of MetS in men with LUTS was reported in many studies. Although the exact biological pathway is not clear yet, insulin resistance, increased visceral adiposity, sex- hormone alterations and cellular inflammatory reactions played significant roles in the related pathophysiological processes. Clinician should recognize the cardiovascular and metabolic impacts of MetS in men with LUTS, early risk- factors optimization and use of appropriate medical therapy may possibly alter or slower the progression of LUTS/BPH, and potentially avoid unnecessary morbidities and mortalities from cardiovascular and metabolic diseases for men.

MetS has been associated with a state of chronic low grade inflammation, with elevated levels of inflammation markers such as C-reactive protein (CRP) as well as pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin (IL)-8, IL-6, and IL-1p. T-cell activities in prostate inflammatory infiltrates may result in stimulation of stromal and epithelial cell proliferation that is sustained by an autoimmune mechanism. Tissue damages and the subsequent chronic process of repetitive wound healing induced by chronic inflammation may lead to the development of BPH nodules.

Cheng Ling Lee et al. [49]: “The molecular etiology of BPE/ BPH is complicated and poorly understood, several risk factors for the development of BPE/BPH and LUTS have been identified: age, genetics, hormones, growth factors, inflammation, lifestyle factors. Age is the major risk factor for BPE/BPH and LUTS. The aging process involves changes in cellular mitogenesis and hormonal homeostasis in the prostate gland, which later proceed to chromosomal aberration and apoptosis. Also associated with inflammation and microvascular disease, which provoke ischemia and oxidative stress, providing a favorable environment for BPH. A genetic link for clinical BPH in men younger than 60 years has been studied over the past years. Evidence suggests that it is an inheritable disease, possibly in an autosomal dominant fashion. Moreover, the genetic factor is said to account for a 72% increased risk in developing moderate or severe LUTS in elderly men.

Sex steroid hormones have been affirmatively linked with the development and maintenance of BPE/BPH. Androgen is the most extensively studied hormone of all. In the prostate, testosterone is converted to dihydro-testosterone (DHT) by type II 5α reductase through DHT/androgen receptor signaling and may influence cell proliferation, differentiation, morphogenesis, and functional maintenance. The use of 5α reductase inhibitors in a clinical setting was found to decrease serum concentrations of DHT and slow- progression of clinical BPH. Although not yet conclusive, estrogens (both endogenous and exogenous) and selective estrogen receptor modulators may have a role in regulating stromal-epithelial interactions involved in prostatic cellular growth. there is no clear and consistent link between other sex steroid hormones and BPE/BPH.

Many growth factors and their corresponding receptors have been identified in prostatic epithelium and stroma, which can stimulate or inhibit cell-l division and differentiation processes. (epidermal growth factor, fibroblast growth factor, and transforming growth factor-β, but this list is by no means exhaustive.) Activation of these kind of growth factors can induce stromal cell growth, followed by significant tissue remodeling, which is responsible for prostate enlargement. Growing evidence that suggests that inflammation is closely linked to the development of BPE/BPH and LUTS. inflammatory infiltrates are the most prevalent feature coexisting with BPH, the degree of inflammation is correlated with prostate volume and weight, inflammation may activate the release of cytokines and raise the concentration of growth factors, resulting in an abnormal proliferation of prostatic cells. an increased level of C-reactive protein has been observed in men with LUTS, which is likely indicative of systemic inflammation.

In a recent systematic review of metabolic syndrome (MetS) and BPE/BPH focusing on subsets of MetS and their relationship with the TPV and LUTS, it was reported that the TPV was significantly larger in men with MetS than those without. the differences in TPV were significantly higher in obese participants and those with low serum high-density lipoprotein cholesterol levels. Interestingly, in contrast to other studies, there were no differences in LUTS symptom scores between men with and without MetS. Heavy smoking, low physical activity, and high protein intake can also substantially alter the risks of symptomatic BPH and LUTS [49].

Bader MS et al [50] writed that: “UTI caused by antibioticresistant Gram-neg bacteria are a growing concern due to limited therapeutic options. Gram-neg, specifically Enterobacteriaceae, are common causes of community-acquired / hospital acquired UTIs. These micro-organisms can acquire genes that encode for multiple antibiotic- resistance mechanisms, including extended-spectrum-lactamases (ESBLs), AmpC- β -lactamase, carbapenems. The assessment of suspected UTI includes identification of characteristic symptoms or signs, urinalysis, dipstick or microscopic tests, and urine culture if indicated. UTIs are categorized according to the location (upper versus lower urinary tract) and severity (uncomplicated/complicated). Increasing rates of antibiotic resistance necessitate judicious use of antibiotics through the application of antimicrobialstewardship. Knowledge of the common causative pathogens of UTIs including local susceptibility patterns are essential in determining appropriate empiric therapy. The recommended first-line empiric therapies for acute uncomplicated bacterial cystitis in otherwise healthy adult non-pregnant females is a 5-day course of nitrofurantoin or a 3-g single dose of Fosfomycin tromethamine. 2-line options include fluoroquinolones and β-lactams, such as amoxicillin-clavulanate. Current treatment options for the UTIs due to AmpC- β -lactamase-producing organisms include: Fosfomycin, nitrofurantoin, fluoroquinolones, cefepime, piperacillin-tazobactam and carbapenems. treatment options for UTIs due to ESBLs-producing Enterobacteriaceae include nitrofurantoin, Fosfomycin, fluoroquinolones, cefoxitin, piperacillin-tazobactam, carbapenems, ceftazidimeavibactam, metolazone-tazobactam, and aminoglycosides. Based on identification and susceptibility results, alternatives to carbapenems may be used to treat mild-moderate UTIs caused by ESBL-producing Enterobacteriaceae. Ceftazidime-avibactam, colistin, polymyxin B, Fosfomycin, aztreonam, aminoglycosides, tigecycline are treatment options for UTIs caused by carbapenemresistant Enterobacteriaceae (CRE). Treatment- options for UTIs caused by multidrug resistant (MDR)-Pseudomonas spp. include fluoroquinolones, ceftazidime, cefepime, piperacillin-tazobactam, carbapenems, aminoglycosides, colistin, ceftazidime-avibactam, and cefdaloxime-tazobactam. The use of fluoro-quinolones for empiric treatment of UTIs should be restricted due to increased rates of resistance. Aminoglycosides, colistin, and tigecycline are considered alternatives in MDR Gram-negative infections in patients with limited therapeutic options” [50].

According Huang Z et al. [51]: “The purpose of this study was to investigate the incidence and risk factors of male urinary tract infection (UTI) after urodynamic study (UDS). A total of 854 consecutive male patients, who underwent UDS at Peking Union Medical College Hospital from January 2010 to March 2016, were recruited in this study. Two to four weeks before the examination, urinalysis with bacterial culture was performed. Patients with negative results were selected for UDS. Immediately before the examination, urinalysis was repeated to rule out any preoperative UTI. Between 48 and 72h after the exam, urine culture was performed again to determine the incidence of UTI. The incidence of UTI and patients’ baseline characteristics, including age, medical history, urodynamic parameters, current diagnosis and pathogen type, were analyzed. Among the 854 patients undergoing UDS, urinary infection was found in 84 cases after the examination, the incidence was 9.83%. Comorbidity with diabetes, post void residual (PVR), volume of prostate (Vp), and two urodynamic parameters, maximal flow rate (Qmax) and average flow rate (Qav) were found to be the independent risk factors for UTI after UDS. The most common pathogens were Escherichia coli (54.76%) and Enterococcus faecalis (19.05%). The incidence of UTI after UDS in male patients was 9.83%. Patients who suffered from comorbidity of diabetes, high PVR, high Vp, low Qmax or Qav may need to be treated with prophylactic antibiotics to prevent postoperative UTI” [51].

Discussion

Lower urinary tract function is influenced by various condition like bladder over-reactivity, neurological disease, Obstructions, chemical cystitis, bladder irritants substantives, infectious (upper and lower UT, complicate or not), stenosis and other with final failure of the excretory function. Also, a fine regulation, when possible, of blood glucose level in diabetes type 2, reduce recurrent cystitis. (glucose is a microbe’s factor growth). But also, to behavior habits, diet and other factor that can influence the complex physiology of LUT.

In some LUT disease near first choice classic drugs other molecules must be considered in order to stop or reduce the vicious circle (BHP, chronic prostatitis). Considering some condition like chronic prostatitis also under an immunologic condition can help in progression control. An improve in pharmacokinetics is needed for example in BPH and chronic prostatitis as well as in Prostatic cancer. (better prostatic tissue perfusion of drugs). Effective antimicrobials, right resistance profile evaluation, punctuality during of therapy, Right associations produce better results. (in example antimicrobial used in urinary tract infectious disease as first choice or second: trimethoprim/sulfamethoxazole, nitrofurantoin, moxifloxacin, ciprofloxacin, levofloxacin, ceftriaxone, piperacillin–tazobactam, Fosfomycin (oral or parenteral, meropenem, ceftazidime/avibactam, cefdaloxime – tazobactam eravaciclin, plasmin and other).

Also new segmentation strategies can improve clinical efficacy in example top think to intra-arterious to perfuse more adequately Urothelium in interstitial cystitis. (antioxidants, antiinflammatory molecule, antimicrobials and other). (innovative New Pharmaceutical drug delivery systems are the right tools). It seems the drugs cannot be not efficient because almost 95% of the drug is wasted to non-target locations even causing toxicity instead of therapeutic response. At the present time, Ciprofloxacin, antioxidants like vitamin C and vitamin E, anti-inflammatory drugs, are reaching the target through urine

In example for interstitial cystitis, If we can deliver the drugs site specifically to the capillary bed of the specific muscle, and we can sustain the drug levels at the target tissue, preventing its fall prematurely, we may be able to not only stop inflammation, and even the radical chain, causing the dysfunction of the muscles, but we even can better kill the bacteria that causes all those chains of reactions. Strategy must be therefore, finding a technology, which can site specifically reach those muscles without unnecessarily wasting the drug all over the body and at the same time other tissues, with not only achieving an increase of the drug level at the the target, but also maintaining the drug levels for a longer period of time, stopping the drop of the concentration in the target, This obviously, not would, but not only will increase the potency of the drug but also eliminate almost all side effects. Obviously, even with no clinical trials, we still can guess what kind of scenario we will have. The treatment of interstitial cystitis is very complex and can involve many therapeutic approaches like: physical therapy or alternative therapies, guided imagery, massage, energy therapy, acupuncture, bladder distention, bladder instillations (mixtures including DMSO, sodium hyaluronate, Heparin, Intravesical pentosan polysulfide Intravesical chondroitin sulfate (CS), Intravesical alkalinized lidocaine, Intravesical oxybutynin and others). surgery to repair Hanner’s lesions, laser surgery, neuromodulation, use of electrical nerve stimulators injections Botox.

Oral medications that can be taken for the pain

Anti-depressives, Amitriptyline, histamine blockers like Cimetidine, antihistamines Hydroxyzine, Oral pentosan polysulfide, immunosuppressant like Cyclosporine A, mycophenolate, Quercetin, Hydrodistension (HD), Triamcinolone (steroid) injection (for Hanner’s lesions), narcotic-non-narcotic medications. some topical medications, as lidocaine patches, vaginal or rectal diazepam, topical amitriptyline, alpha blockers, some antiseizure drugs like gabapentin, leukotriene inhibitors, prostaglandins, NSAIDS, ibuprofen, urinary antacids, potassium or sodium citrate, trinitrates, urinary tract antispasmodics, tolterodine, herbal therapies. Other factor to be considered: In evolution of human species ancient monkeys’ progenitor was not erectus. And today bath habits with sitting methods on an artificial water is different from Ancestral natural urinate process. Also, a dynamic flowmetry could be a real interesting instrument to evaluate Drugs effect (normal- basal, versus after antimicrobials, anti-inflammatory, alpha blockers Et other) in routinely urologic visits to verify on field the single patient response to drugs and to prevent vicious circle.

This make possible to reduce number of relapses when possible and a complexity reducing in Antimicrobials used preventing also resistance pattern diffusion. According Rehan Nasir Khan et al: “Sitting position stretches the puborectalis muscle and slightly closes urogenital hiatus, causing slight obstruction at urogenital hiatus during micturition, at sitting position independent to presence or absence of any bladder outlet obstruction. This relation can also be correlated anatomically. It was found the average angle between rectum and anal canal was 92° while sitting and becomes 132° when the patient gets to squatting position. This change in angle may lead to the relaxation of puborectalis muscles leading to an easier bladder and bowel evacuation”. According the result of Rehan Nasir Khan et al study, “In standing position the maximum flow rate was 32.4±9.6ml/ sec, average flow rate 8.8±16.9ml/sec, and post-void residue was 8.8±16.9ml. In sitting position, the maximum flow rate was 14.8±5.4ml/sec, average flow rate 14.8±5.4ml/sec, and post-void residue was 6.6±9.4ml. A significant difference in both voiding positions was observed regarding the maximum flow rate, average flow rate (p=0.001; p=0.003). The difference was not significant for voided volume (p=0.676), or post-void residual volume (p=0.771) in the either position.” We think then even the pee position and related change (stand or sitting in men) on urinary flow must be deeply investigated in more objective way to prevent the overuse in antimicrobials therapy if not really necessary. A better flux, or voiding time contribute in the global bladder functions. “The maximal flow rate (Qmax) and the average flow rate (Qav) were found to be the independent risk factors for UTI after UDS” [51].

Conclusion

Related the result of bibliography analyses reported a functional- pharmacological toxicological approach can be useful in various lower urinary tract condition (global receptor profile, Bhp and chronic prostatitis right therapy, bladder and prostate irritants, diabetes control, functional and anatomic strictures, neurologic disease and other). The pathologic vicious cycle we have seen contribute in high way in progression. New strategies, new combination of drugs, combination with phototherapy, new delivery system, biofilm agents and, micro-calcifications role in chronic prostatitis, MDR control strategies, right pharmacological kinetics, adequate local drug persistence, better sub ministration strategies can improve the clinical endpoint. (Observing the complete receptor equipment like an orchestra) Normal urinary flow is a very complex - synchronized system, it depend by different factors: detrusor contractility, urothelium floosy, urethral resistance, autonomic and voluntary nerve innervations status, abdominal straining and other factors like genetics (see some prostatic cancer) and immunologic status (see the role played in Bhp) or metabolic status (in ex diabetes, metabolic syndrome), hormonal influence, growth factors ,diet (irritants), infections , water intake habit, psychological profile, stressing conditions by also to postural errors (sedentariness’s, jobs), pee habit, and many other. All factors to be considered to make possible to better manage some anti-microbials currently used in some LUT conditions.

Clarification

This works is produced under a pharmaceutical point of view and with no any diagnostic or therapeutic intent, only to produce new research hypothesis.

References

1. Kogan P, Xu S, Wang Y, Donnell O, Lutgendorf SK, et al. (2018) Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study 26: 8(1): 6573.
2. Fiander N (2013) Painful bladder syndrome and interstitial cystitis: treatment options. Br J Nurs 9-22(9): S26-S33.
3. Wyman JF, Burgio KL (2009) Newman DK Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract 63(8): 1177-1191.
4. Kaddumi EG, Hubscher CH (2007) Urinary bladder irritation alters efficacy of vagal stimulation on rostral medullary neurons in chronic T8 spinalized rats J Neurotrauma 24(7): 1219-1228.
5. Shorter B, Lesser M, Moldwin RM, Kushner L (2007) Effect of comestibles on symptoms of interstitial cystitis J Urol 178(1): 145-152.
6. Ellenbroek JH, Arioglu Inan E, Michel MC (2018) A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences. Neurourol Urodyn 37(8): 2346-2360.
7. Tong YC1, Chin WT, Cheng JT (2002) Role of sorbitol in the up-regulation of urinary bladder M (2) muscarinic receptors in streptozotocin-induced diabetic rats Neurourol Urodyn 21(2): 154-159.
8. Liu BK, Jin XW, Lu HZ, Zhang X, Zhao ZH, et al. (2018) The Effects of Neurokinin-1 Receptor Antagonist in an Experimental Autoimmune Cystitis Model Resembling Bladder Pain Syndrome/Interstitial Cystitis. Inflammation.
9. Butler DSC, Ambite I, Nagy K, Cafaro C, Ahmed A, et al. (2018) Neuroepithelial control of mucosal inflammation in acute cystitis 8(1): 11015.
10. Tourret J, Bagnis CI, Denamur E (2014) Urinary tract infections in diabetic patients 64(7): 980-983.
11. Ross MA (1993) Neuropathies associated with diabetes. Med Clin North Am 77(1): 111-124.
12. Am J (2013) Impact of diabetes mellitus on bladder uroepithelial cells Physiol Regul Integr Comp Physiol 304(2): R84-R93.
13. L Birder W, de Groat, Mills, J Morrison, K Thor, et al. (2010) Neural Control of the Lower Urinary Tract: Peripheral and Spinal Mechanisms Neurourol Urodyn 29(1): 128-139.
14. Thor KB, Katofiasc MA, Danuser H, Springer J, Schaus JM (2002) The role of 5-HT(1A) receptors in control of lower urinary tr act function in cats. Brain Res 946(2): 290-297.
15. Mauro luisetto, Behzad Nili Ahmadabadi, Ghulam Rasool Mashori, Ram Kumar Sahu, Farhan Ahmad Khan, et al. (2018) Immunitary role in chronic prostatitis and growth factors as promoter of BPH. Insights Clin Cell Immunol Insights in Clinical and Cellular Immunology 2: 001-013.
16. M Nili Ahmadabadi B (2017) Chronic Prostatitis: The Clinical Pharmacist Role and New Delivery Systems. J Bioanal Biomed 1000: e151.
17. Luisetto M, Behzad NA, Ghulam RM (2017) Relapses and Recurrent Chronic Bacteric Prostatitis - Biofilm Related, A Case Report. J of Pharmacol & Clin Res 4(4): 555644.
18. Xu Z, Jia RP (2018) PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction. Zhonghua Nan Ke Xue 24(4): 355-359.
19. Magri V, Marras E, Restelli A, Wagenlehner FM, Perletti G (2015) Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med 9(3): 658-666.
20. Ozaki T, Matsuoka J, Tsubota M, Tomita S, Sekiguchi F, et al. (2018) Zinc deficiency promotes cystitis-related bladder pain by enhancing function and expression of Cav3.2 in mice. Toxicology 393: 102-112.
21. Lovick TA (2016) Central control of visceral pain and urinary tract function. Auton Neurosci 200: 35-42.
22. Tonon L, Fromont G, Boyault S, Thomas E, Ferrari A, et al. (2018) Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men. Eur Urol S0302-2838(18): 30618-30623.
23. Firouz Daneshgari, Guiming Liu, Lori Birder, Ann T Hanna Mitchell, Samuel Chacko, et al. (2009) Diabetic Bladder Dysfunction: Current Translational Knowledge J Urol 182(6): S18-S26.
24. Montalbetti N, Rued AC, Taiclet SN, Birder LA, Kullmann FA, et al. (2017) Urothelial Tight Junction Barrier Dysfunction Sensitizes Bladder Afferents 24: 4(3).
25. Helen L Nicholson, Yasser Al Hakeem, Javier J Maldonado, Vincent T, et al. (2017) Management of bladder neck stenosis and urethral stricture and stenosis following treatment for prostate cancer. Transl Androl Urol 6(Suppl 2): S92-S102.
26. Zhao Z, Zhang J, He J, Zeng G (2013) Clinical utility of the UPOINT phenotype system in Chinese males with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a prospective study. PLoS One 8(1): e52044.
27. Kim Moon, Sohng I, Lee HW, Lee G, Lee JG, et al. (1999) Effects of ethanol and its metabolite acetaldehyde on responses of the rat bladder. Wiley Online Library 83(6): 689-692.
28. Magistro G, Wagenlehner FM, Grabe M, Weidner W, Stief CG, et al. (2016) Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Eur Urol 69(2): 286-297.
29. Bayrak O, Erturhan S, Seckiner I, Erbagci A, Ustun A, et al. (2014) Chemical cystitis developed in experimental animals model: Topical effect of intravesical ozone application to bladder. Urol Ann 6(2): 122-126.
30. Subhash Haldar, Christopher Dru, Neil A Bhowmick (2014) Mechanisms of hemorrhagic cystitis. Am J Clin Exp Urol 2(3): 199-208.
31. Saeid Golbidi, Smail Laher (2010) Bladder Dysfunction in Diabetes Mellitus Front Pharmacol 1: 136.
32. Victor W Nitty (2005) Primary Bladder Neck Obstruction in Men and Women. Rev Urol 7(Suppl 8): S12-S17.
33. Chen C, Zeng M, Xue R, Wang G, Gao Z, et al. (2018) Causes and management for male urethral stricture. 43(5): 520-527.
34. Simon van Rij, Peter Gillinga (2015) Recent advances in treatment for Benign Prostatic Hyperplasia Version 4: F1000.
35. Rehan Nasir Khan, Syed Zafar, Zaidi J (2017) Pakistan medical association Comparison of position-related changes on uroflowmetric parameters in healthy young men (The Indus Hospital, Karachi.) 67(6): 839-842.
36. Gravas S, Samarinas M, Zacharouli K, Karatzas A, Tzortzis V, et al. (2018) The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World J Urol.
37. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, et al. (2011) Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats 8(10): 2746-60.
38. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, et al. (2010) Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract 7(1 Pt 1): 59-69.
39. Krivoborodov GG, Shumilo DV, Basil AV, Tur EI, Poddubnaia NV, et al. (2011) Botulinic toxin type a in combined treatment of males with chronic pelvic pain syndrome in combination with bladder emptying dysfunction. Urologiia (5): 67-72.
40. Zhanel GG, Zhanel MA, Karlowsky JA (2018) Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli. Can J Infect Dis Med Microbiol 2: 1-9.
41. Carsten Niemitz (2010) The evolution of the upright posture and gait-a review and a new synthesis Naturwissenschaften 97(3): 241-263.
42. Whi An Kwon (2018) Animal Model of Interstitial Cystitis/Bladder Pain Syndrome Int Neurourol J 22(Suppl 1): S1-S2.
43. Avril Lusty, Elizabeth Kavaler, Kay Zakariasen, Victoria Tolls, J Curtis Nickel, et al. (2018) Treatment effectiveness in interstitial cystitis/bladder pain syndrome: Do patient perceptions align with efficacy-based guidelines? Can Urol Assoc J 12(1): E1-E5.
44. Kristina Cvach, Anna Rosamilia (2015) Intravesical therapies for bladder pain syndrome/interstitial cystitis Transl Androl Urol 4(6): 629-637.
45. Sudhindra Jayasimha (2017) Nanotechnology in Urology. Indian J Urol 33(1): 13-18.
46. Martino Maria Zacchè, Sushma Srikrishna, Linda Cardozo (2015) Novel targeted bladder drug-delivery systems 7: 169-178.
47. Apul Goel, Gautam Kanodia, Ashok Kumar Sokhal, Kawaljit Singh, Monica Agrawal, et al. (2017) Evaluation of Impact of Voiding Posture on Uroflowmetry Parameters in Men. World J Mens Health 35(2): 100-106.
48. Ho Yin Ngai, Kar Kei Steffi Yuen, Chi-Man Ng, Cheung-Hing Cheng, Sau Kwan Peggy, et al. (2017) Chub Metabolic syndrome and benign prostatic hyperplasia: An update Asian J Urol 4(3): 164-173.
49. Cheng Ling Lee, Hann Chorng Kuo (2017) Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts 29(2): 79-83.
50. Bader MS, Loeb M, Brooks AA (2017) An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med 129(2): 242-258.
51. Huang Z, Xiao H, Li H, Yan W, Ji Z, et al. (2017) Analysis of the incidence and risk factors of male urinary tract infection following urodynamic study. Eur J Clin Microbiol Infect Dis 36(10): 1873-1878.